Uterine Manipulator Versus no Uterine Manipulator in Endometrial Cancer Trial

Inclusion criteria

• Diagnosis of Endometrial Cancer of any histology (including carcinosarcoma) and grade
• Planned surgical treatment including hysterectomy and bilateral salpingo-oophorectomy (ovarian preservation in selected patients is not an exclusion criterion)
• Age ≥ 18 years
• No preoperative evidence of extrauterine disease (Clinical stage IIIA, IIIB)
• No preoperative evidence of suspicious lymph nodes (Clinical stage IIIC)
• No preoperative evidence of distant metastasis (Clinical stage IV)
• Approved and signed informed consent

Exclusion criteria

• Neoadjuvant therapy
• Synchronous or previous (< 5 years) invasive cancer, not including non-melanoma skin cancer
• Fertility preservation
• World Health Organization performance score > 2
• Uterine sarcoma
• Previous pelvic/abdominal radiotherapy, hormone therapy for cancer (< 5 years), chemotherapy (< 5 years), pelvic or paraaortic lymphadenectomy, or retroperitoneal surgery
• Inadequate bone marrow function (white blood cells <3·0×109/L, platelets <100×109/L)
• Inadequate liver function (bilirubin >1.5×upper normal limit [UNL], aspartate aminotransferase, and alanine aminotransferase >2.5 × UNL)
• Inadequate kidney function (creatinine clearance < 60 mL per min calculated according to Cockcroft-Gault 10 or < 50 mL per min Ethylenediaminetetraacetic acid clearance)
• Intraoperative evidence of stage IV disease